Astellas Pharma (ALPMY)
(Delayed Data from OTC)
$11.66 USD
-0.02 (-0.17%)
Updated Nov 1, 2024 03:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALPMY 11.66 -0.02(-0.17%)
Will ALPMY be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for ALPMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALPMY
Are Investors Undervaluing Astellas Pharma (ALPMY) Right Now?
ALPMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ALPMY
Astellas Pharma (ALPMF) Receives a Hold from Jefferies
Astellas Pharma Inc. (ALPMF) Q2 2024 Earnings Call Transcript
Apellis a new sector perform at RBC on Syfovre expectations
Bernstein Releases a Buy Rating on Astellas Pharma (ALPMF)
Astellas wins FDA nod for first-line gastric cancer therapy